Puma slips on neratinib NDA delay

Puma Biotechnology Inc. (NYSE:PBYI) fell $7.45 (21%) to $27.92 on Tuesday after it said it would submit an NDA for oral neratinib (PB272) in mid-2016, later than expected,

Read the full 288 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE